药物临床试验登记与信息公示平台数据显示,广东恒瑞医药有限公司/上海恒瑞医药有限公司的评价SHR-3045注射液在中至重度活动性类风湿关节炎患者中有效性和安全性的随机、双盲、安慰剂对照的IIa期研究已启动。临床试验登记号为CTR20254504,首次公示信息日期为2025年11月13日。该药物剂型为注射液,用法用量按方案规定使用。本次试验主要目的为评价SHR-3045注射液在中至重度活动性类风湿...
Source Link药物临床试验登记与信息公示平台数据显示,广东恒瑞医药有限公司/上海恒瑞医药有限公司的评价SHR-3045注射液在中至重度活动性类风湿关节炎患者中有效性和安全性的随机、双盲、安慰剂对照的IIa期研究已启动。临床试验登记号为CTR20254504,首次公示信息日期为2025年11月13日。该药物剂型为注射液,用法用量按方案规定使用。本次试验主要目的为评价SHR-3045注射液在中至重度活动性类风湿...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.